Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein

Clinical trial NCT05132907 · COMPLETED

Trial details

NCT number: NCT05132907
Sponsor: HDT Bio
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

SARS-CoV2 Infection

Start date: 2022-01-24
Primary completion: 2023-11-21
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.